Martin Shkreli (aka Pharma Bro) is an American hedge fund manager, specializing in healthcare businesses, and is a co-founder of MSMB Capital Management. In September 2015, Shkreli was criticized when Turing Pharmaceuticals obtained the manufacturing license for Daraprim, and raised its price by 5,455 percent (from $13.50 to $750 per tablet). After initially defending the price increase, Shkreli said an unspecified lower price would be established, but his poor reputation will remain.
Here is the video:
Newest Investment $KBIO, Pops 700% in After-Hours
In his newest endeavor, he bought 1,211,115 shares in KaloBios Pharmaceuticals Inc ($KBIO) for an average price of $1.34 per share. When his Form4 filing came out today after market hours the stock popped as high as 700%. Meaning that he has gained $15 million in 48 hours, as much as his Martin Shkreli’s Turing Pharmaceuticals, Which Raised AIDS Drug Price 5000%, Loses $14 Million.
Since november 1st there are some 332,804 shares short. At the current trading volume it would take them 7 days to cover those shorts so we will see some interesting trading activity tomorrow.
